Rasilamlo Articles
Germany’s IQWiG finds no added benefit for Novartis’ Rasilamlo
21 February 2012
Novartis gains positive CHMP opinion for Rasilamlo, as do CSL Behring for Hizentra and Provepharm for Proveblue
21 February 2011
Showing 1-3 of 3 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
